ABOUT
Kaass Discovery develops peptide immunomodulators validated through independent, blinded preclinical studies conducted with global CRO partners.
​
Founded on PhD research from the University of Oslo, this privately held Norwegian biotechnology company operates as a lean, asset-focused organization with flexibility for strategic partnerships and global growth.​​​
Independent, blinded efficacy
Prophylactic CIA: significantly reduced disease activity, head-to-head outperformed anti-TNF.
Therapeutic CIA (post-induction): significantly reduced disease severity versus vehicle. Studies conducted with Charles River Laboratories.
Efficacy demonstrated in multiple sclerosis (EAE). Studies conducted with Redoxis.
Ongoing preclinical studies are evaluating cardiovascular inflammation (ApoE-/-) and Alzheimer’s disease (5xFAD); analyses are pending.
PIPELINE & SCIENCE
From conserved biology to cross-disciplinary therapies
Our peptides modulate a conserved endocrine–immune pathway to recalibrate inflammatory responses upstream of cytokine cascades.
​
This pathway is deeply conserved across more than 500 million years of evolution, underscoring its central role in systemic physiology and relevance to immune regulation.
Our anchor program in rheumatoid arthritis is supported by compelling in vivo data. Building on this foundation, we are exploring additional indications where immune dysregulation plays a central role.
​
​
CIA: Head-to-head outperformed anti-TNF in prophylactic CIA. Significant reduction of disease severity versus vehicle in therapeutic CIA. No microscopic features of disease activity in therapeutic or prohylactic CIA. Studies conducted by Charles River Laboratories.​
​
EAE: Significant improvement at key time points in a neuroinflammation (EAE) model performed by Redoxis. A new dose-optimization study is underway.
​
CVD (ApoE-/-): Ongoing circulating immune-cell and serum biomarker endpoints. Plaque analysis pending. Data to date indicate systemic immunomodulation.
​
Alzheimer´s (5xFAD): Full clinical read-out pending.
​
Consistent safety and tolerability across all completed studies.
​​
​​
SCIENTIFIC DEVELOPMENT
& SUPPORT
Our programs are advanced with the support of trusted CROs and research providers:
LEGAL & IP COUNSEL
We are supported by leading global intellectual property and legal advisors, including Cooley LLP and Dehns.
FUNDING & SUPPORT
We are grateful for the support of leading innovation agencies and programs:
TEAM
Dr. Anita Kåss, MBChB (Hons) PhD is the founder and CEO of Kaass Discovery, established from her PhD research at the University of Oslo and more than 20 years of experience as a practicing physician. Clinical observations were fundamental to identifying the endocrine–immune interface as a novel therapeutic axis and remain central to the company’s approach. She combines drug discovery, translational research, and intellectual property expertise with direct patient insight. Dr. Kåss is also the author of The Immune Mystery, underscoring her unique perspective at the intersection of medicine, science, and communication.
Preben Hjallum is the COO at Kaass Discovery. He is responsible for corporate development, partnerships, and overall business strategy, ensuring that Kaass Discovery advances efficiently as a lean, asset-focused biotech. Preben brings experience from leadership roles across several health companies, providing a broad network and cross-sector perspective that support the company’s global partnering ambitions.